Recent Advances in Management of Renal Cell Carcinoma

Dear Colleagues,

First-line treatments with advanced renal cell carcinoma (aRCC) include immune check-point inhibitors used as dual-type combinations (ipilimumab and nivolumab) or tyrosine kinase inhibitors (nivolumab with cabozantinib, pembrolizumab with axitinib or levantinib, and avelumab with axitinib). Significant progress has been made in treatment of aRCC, and newer combinations are being investigated. Other drugs that inhibit hypoxia-inducible factor (HIF) and vascular endothelial growth factor (VEGF) signaling have demonstrated survival advantage. Tyrosine kinase inhibitors and mTor inhibitors have also shown an ability to inhibit aRCC growth. Key questions to answer in aRCC management include how to combine and sequence different types of therapies, as well as how to integrate new approaches in aRCC management. 

The aim of this Special Issue is to define molecular and cellular targets in treating aRCC, including (1) the genetic basis and/or epigenetic mechanism of RCC; (2) drug resistance; (3) newer imaging modalities in diagnosis; (4) rare types of RCC; (5) newer drugs in aRCC treatment; (6) and real-world studies in aRCC. This Special Issue welcomes both original research articles and reviews.

Dr. Anand Sharma
Prof. Dr. Nikhil Vasdev
Dr. Prantik Das
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.